Evidence map›Paper›PMID 40162779›Full record

ArticlemBio2025

Terminal complement complexes with or without C9 potentiate antimicrobial activity against

Evan R Lamb, Alison K Criss

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Plasma Proteomic Profile of Chemotherapy-Induced Severe Neutropenia: A Pilot Discovery Phase Study.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Evan R LambDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0002-1759-2423
Alison K CrissDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0001-7738-3757

Funding

BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6M
INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
The Gonorrhea Vaccine Cooperative Research CenterU19AI144180 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI CHACKERIAN, BRYCE C · 2019 to 2023
$10.7M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR01AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI CRISS, ALISON K · 2012 to 2022
$4.6M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR37AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI Alison K Criss · 2025 to 2026
$1.1M
Defining mechanisms of complement-mediated killing of Neisseria gonorrhoeaeF30AI179038 · NIAID · UNIVERSITY OF VIRGINIA · PI LAMB, EVAN R · 2024 to 2025
$93k
National Institute of Allergy and Infectious Diseases F30AI179038National Institute of Allergy and Infectious Diseases R01AI097312National Institute of Allergy and Infectious Diseases T32AI007046National Institute of Allergy and Infectious Diseases U19AI144180NHLBI NIH HHS T32 HL007284NIAID NIH HHS F30 AI179038NIAID NIH HHS R01 AI097312NIAID NIH HHS R37 AI097312NIAID NIH HHS T32 AI007046NIAID NIH HHS U19 AI144180NIGMS NIH HHS T32 GM007267NIGMS NIH HHS T32GM007267University of Virginia Harrison Distinguished Teaching Professorship
6 · The paper itself

Abstract

The complement cascade is a front-line defense against pathogens. Complement activation generates the membrane attack complex (MAC), a 10-11 nm diameter pore formed by complement proteins C5b through C8 and polymerized C9. The MAC embeds within the outer membrane of Gram-negative bacteria and displays bactericidal activity. In the absence of C9, C5b-C8 complexes can form 2-4 nm pores on membranes, but their relevance to microbial control is poorly understood. Deficiencies in terminal complement components uniquely predispose individuals to infections by pathogenic IMPORTANCE: The complement cascade is a front-line arm of the innate immune system against pathogens. Complement activation results in membrane attack complex (MAC) pores forming on the outer membrane of Gram-negative bacteria, resulting in bacterial death. Individuals who cannot generate MAC are specifically susceptible to infection by pathogenic

Indexed as

Anti-Bacterial AgentsComplement C9Complement Membrane Attack ComplexNeisseria gonorrhoeaeAzithromycinComplement ActivationGonorrheaHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAzithromycinComplement C9Complement Membrane Attack Complexantimicrobial resistancecomplementinnate immunitymembrane attack complexNeisseriaNeisseria gonorrhoeae

Identifiers

PMID40162779
PMCPMC12077172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.